1. Scrip
  2. >>Business
  3. >>Deals

FTC’s Challenge Of Amgen/Horizon Merger Seeks To Fight Pharma Rebating Practices

Lawsuit Does Not Cite Overlap In Companies’ Portfolios

 
• By Mandy Jackson

The US Federal Trade Commission is taking a stand against rebating and bundling practices pharma companies use in negotiations with payers as it seeks to block Amgen’s $28bn acquisition of Horizon.

FTC FEDERAL TRADE COMMISSION headquarters building entrance with sign above door and exterior.
The FTC is calling out Amgen for bundled rebate practices • Source: Shutterstock

The US Federal Trade Commission is taking its fight against rebating and bundling practices that pharmaceutical companies employ in negotiations with payers to court, but not by suing to stop these tactics directly. Instead, the FTC said on 16 May that it is filing a lawsuit to block Amgen, Inc.’s $28bn purchase of Horizon Therapeutics plc to prevent the acquirer from obtaining greater power to block competition through drug price rebates it promises to pharmacy benefit managers (PBMs).

KEY TAKEAWAYS

  • The action represents a new tactic for the agency, seeking to block Amgen’s acquisition of Horizon because of the power it will have to affect market access via bundled drug price rebates.

The FTC did not point to any overlap in the two companies’ product portfolios or research and development pipelines, the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

A MoonLake Buyout Would Boost Merck & Co’s Immunology Ambitions

 
• By Andrew McConaghie

As the patent protection clock ticks down on Merck’s flagship blockbuster Keytruda, the company is reported to be pursuing the inflammation and immunology biotech. Such a move would bulk up its sparse I&I pipeline.

Deal Watch: Lilly Licenses Camurus’s Delivery Technology For Long-Acting Incretins

 
• By Joseph Haas

Plus deals involving Roche/Vividion, Alto/Chase, Biogen/City Therapeutics, Sanofi/Nurix and Naya/Invo.

Degron Eyes Deals For Novel Molecular Glue Degrader Assets

 
• By Dexter Jie Yan

Pursuing first-in-class molecular glue degraders using undruggable targets could eventually help Degron Therapeutics land sizable asset-based deals, CEO Lily Zou tells Scrip.

Kymera STAT6 Data Set The Bar For ‘Dupixent-In-A-Pill’ Race

 
• By Jessica Merrill

Kymera will move KT-621 into Phase II trials later this year based on compelling data in healthy volunteers, validating the company’s protein-degradation platform.

More from Business

Finance Watch: Is Six The Magic Number? May Sees Half Dozen VC Mega-Rounds

 
• By Mandy Jackson

Private Company Edition: Six biopharma companies raised venture capital rounds totaling $100m or more in May, matching the number of mega-rounds in April and March. Among other recent financings, Syndeio launched with $90m and SpyGlass raised a $75m series D round.

Bayer Boosted By Third FDA Approval For Nubeqa

 
• By Kevin Grogan

US green light will further expand sales of the prostate cancer blockbuster.

Kymera STAT6 Data Set The Bar For ‘Dupixent-In-A-Pill’ Race

 
• By Jessica Merrill

Kymera will move KT-621 into Phase II trials later this year based on compelling data in healthy volunteers, validating the company’s protein-degradation platform.